Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses SGHT in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named SGHT in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Paul Badawi | $659,000 | $0 | $1,000,000 | $0 | $334,607 | $0 | $12,001 | $2,005,608 |
| President and Chief Executive Officer | ||||||||
| Alison Bauerlein | 474,900 | 0 | 950,000 | 0 | 196,504 | 0 | 5,250 | 1,626,754 |
| Chief Operating Officer | ||||||||
| Matthew Link | 288,125 | 0 | 480,000 | 0 | 0 | 0 | 448,793 | 1,216,918 |
| Chief Commercial Officer | ||||||||
| Jeremy Hayden | 433,000 | 0 | 390,000 | 0 | 146,571 | 0 | 4,683 | 974,254 |
| Chief Legal Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Paul Badawi | $2,005,608 | $3,022,179 | — | −1,016,571 |
| Alison Bauerlein | 1,626,754 | 2,238,543 | — | −611,789 |
| Matthew Link | 1,216,918 | — | — | — |
| Jeremy Hayden | 974,254 | 1,479,652 | — | −505,398 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Paul Badawi | RSU | 88,300 | — | $700,219 |
| Alison Bauerlein | RSU | 157,711 | — | 1,250,648 |
| Alison Bauerlein | RSU | 215,054 | — | 1,705,378 |
| Paul Badawi | RSU | 268,818 | — | 2,131,727 |
| Paul Badawi | RSU | 195,094 | — | 1,547,095 |
| Jeremy Hayden | RSU | 75,935 | — | 602,165 |
| Jeremy Hayden | RSU | 104,839 | — | 831,373 |
| Alison Bauerlein | RSU | 51,500 | — | 408,395 |
| Jeremy Hayden | RSU | 22,935 | — | 178,822 |
| Paul Badawi | RSU | 21,950 | — | 174,064 |
| Alison Bauerlein | RSU | 21,569 | — | 171,042 |
| Jeremy Hayden | RSU | 3,000 | — | 23,790 |
| Paul Badawi | Option | 7,319 | 17.52 | — |
| Paul Badawi | Option | 61,128 | 9.78 | — |
| Alison Bauerlein | Option | 19,722 | 10.1 | — |
| Jeremy Hayden | Option | 1,055 | 17.52 | — |
| Jeremy Hayden | Option | 15,628 | 9.78 | — |
The executive compensation program is designed to be competitive and appropriately balance the goals of attracting and retaining executives and motivating them to achieve strategic objectives. It follows a pay-for-performance philosophy where a portion of target annual compensation is variable based on the achievement of business and strategic objectives.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia, Inc. |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Gerhard BurbachIndependent · Compensation Committee (Chair) · Nominating and Corporate Governance Committee · Commercial Strategy Committee | $43,616 | $240,000 | — | — | — | $283,616 |
| Staffan EncrantzIndependent · Board Chair · Audit Committee · Nominating and Corporate Governance Committee (Chair) · Commercial Strategy Committee | 101,000 | 130,000 | — | — | — | 231,000 |
| Donald ZurbayIndependent · Audit Committee (Chair) · Compensation Committee | 72,500 | 130,000 | — | — | — | 202,500 |
| Catherine MazzaccoIndependent · Audit Committee · Commercial Strategy Committee (Chair) | 67,000 | 130,000 | — | — | — | 197,000 |
| Tamara Fountain, M.DIndependent · Audit · Compensation · Nominating and Corporate Governance | 59,606 | 130,000 | — | — | — | 189,606 |
| Erica RogersIndependent · Not standing for re-election · Departed during FY | 55,733 | 130,000 | — | — | — | 185,733 |
| Brenda BeckerIndependent · Not standing for re-election · Departed during FY | 48,556 | 130,000 | — | — | — | 178,556 |
| David Badawi, M.DEmployee director | — | — | — | — | — | 0 |
| Paul BadawiEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $130,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 15,000 / 10,000 |
| Stock ownership guideline | We have adopted Stock Ownership Guidelines applicable to our executive officers and non-employee directors that ensure the interests of our executive officers and directors are aligned with those of our stockholders. |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $448,011 |
| Equity awards (grant-date value) | $1,020,000 |
| All other compensation | $0 |
| Total cost of the board | $1,468,011 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Sight Sciences names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Sight Sciences.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | AxoGen | 2025 | Michael Dale | $775,865 | $7,342,895 | $0 | $906,133 | $9,047,454 |
| 2 | Si-BONE | 2025 | Laura Francis | 685,000 | 6,038,710 | 0 | 729,525 | 7,453,235 |
| 3 | Pulse Biosciences | 2025 | Paul LaViolette | 708,523 | 0 | 6,717,960 | 0 | 7,427,899 |
| 4 | CareDx | 2025 | John Hanna | 693,269 | 5,622,638 | 0 | 852,515 | 7,179,699 |
| 5 | Treace Medical Concepts | 2025 | John Treace | 755,353 | 4,635,000 | 0 | 0 | 5,405,190 |
| 6 | RxSight | 2025 | Ron Kurtz | 630,625 | 0 | 3,816,530 | 202,935 | 4,650,661 |
| 7 | CVRx | 2025 | Kevin Hykes | 660,533 | 1,270,080 | 1,516,896 | 444,492 | 3,905,801 |
| 8 | Senseonics Holdings | 2025 | Timothy Goodnow | 635,000 | 1,022,500 | 1,022,500 | 613,000 | 3,347,959 |
| 9 | OrthoPediatrics | 2025 | David Bailey | 550,000 | 2,445,200 | 0 | 322,281 | 3,331,481 |
| 10 | Sight Sciences | 2025 | Paul Badawi | 659,000 | 1,000,000 | 0 | 334,607 | 2,005,608 |
| 11 | Zynex | 2024 | Thomas Sandgaard | 700,000 | 112,458 | 0 | 170,625 | 991,810 |
| 12 | iRadimed Corporation | 2025 | Roger Susi | 385,598 | 0 | 0 | 395,000 | 780,598 |
| — | ClearPoint Neuro | — | — | — | — | — | — | not in coverage universe |
| — | TELA Bio | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Sight Sciences | not disclosed | RSU 100 | not disclosed | Compensia, Inc. |
| AxoGen | 116.79% | PSU 50 · RSU 50 | No | Aon |
| CareDx | 122% | RSU 70 · PSU 30 | No | Alpine Rewards |
| ClearPoint Neuro | not disclosed | not disclosed | not disclosed | not disclosed |
| CVRx | not disclosed | Option 50 · RSU 50 | not disclosed | Aon |
| iRadimed Corporation | not disclosed | not disclosed | not disclosed | not disclosed |
| OrthoPediatrics | 78.2% | RSU 100 | not disclosed | NFP Compensation Consulting |
| Pulse Biosciences | not disclosed | not disclosed | not disclosed | not disclosed |
| RxSight | 32.18% | Options 100 | not disclosed | Aon Human Capital Solutions |
| Senseonics Holdings | not disclosed | not disclosed | not disclosed | Willis Towers Watson |
| Si-BONE | 106.5% | RSU 50 · PSU 50 | Yes — Relative TSR | Compensia, Inc. |
| TELA Bio | not disclosed | not disclosed | not disclosed | not disclosed |
| Treace Medical Concepts | not disclosed | RSU 50 · PSU 50 | No | Compensia, Inc. |
| Zynex | 24.4% | not disclosed | not disclosed | not disclosed |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Paul Badawi | DEF 14A | 2026-04-22 | 0001140361-26-016138 | Section “2025 Summary Compensation Table” · page 41. As printed: 2,005,608. Filing ↗machine: r2 · c18 · span 798195–798204 |
| 2 | Section 01, Alison Bauerlein | DEF 14A | 2026-04-22 | 0001140361-26-016138 | Section “2025 Summary Compensation Table” · page 41. As printed: 1,626,754. Filing ↗machine: r4 · c18 · span 804906–804915 |
| 3 | Section 01, Matthew Link | DEF 14A | 2026-04-22 | 0001140361-26-016138 | Section “2025 Summary Compensation Table” · page 41. As printed: 1,216,918. Filing ↗machine: r8 · c18 · span 818101–818110 |
| 4 | Section 01, Jeremy Hayden | DEF 14A | 2026-04-22 | 0001140361-26-016138 | Section “2025 Summary Compensation Table” · page 41. As printed: 974,254. Filing ↗machine: r6 · c18 · span 811684–811691 |
| 5 | Section 08, Gerhard Burbach | DEF 14A | 2026-04-22 | 0001140361-26-016138 | Section “Director Compensation”. As printed: 283,616. Filing ↗machine: span 920481–920660 |
| 6 | Section 08, Staffan Encrantz | DEF 14A | 2026-04-22 | 0001140361-26-016138 | Section “Director Compensation”. As printed: 231,000. Filing ↗machine: span 912848–913027 |
| 7 | Section 08, Donald Zurbay | DEF 14A | 2026-04-22 | 0001140361-26-016138 | Section “Director Compensation”. As printed: 202,500. Filing ↗machine: span 922418–922596 |
| 8 | Section 08, Catherine Mazzacco | DEF 14A | 2026-04-22 | 0001140361-26-016138 | Section “Director Compensation”. As printed: 197,000. Filing ↗machine: span 916656–916835 |
| 9 | Section 08, Tamara Fountain, M.D | DEF 14A | 2026-04-22 | 0001140361-26-016138 | Section “Director Compensation”. As printed: 189,606. Filing ↗machine: span 914888–915067 |
| 10 | Section 08, Erica Rogers | DEF 14A | 2026-04-22 | 0001140361-26-016138 | Section “Director Compensation”. As printed: 185,733. Filing ↗machine: span 918702–918881 |
| 11 | Section 08, Brenda Becker | DEF 14A | 2026-04-22 | 0001140361-26-016138 | Section “Director Compensation”. As printed: 178,556. Filing ↗machine: span 911121–911300 |
| 12 | Section 08, David Badawi, M.D | DEF 14A | 2026-04-22 | 0001140361-26-016138 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 13 | Section 08, Paul Badawi | DEF 14A | 2026-04-22 | 0001140361-26-016138 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 14 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 15 | Section 09b board cost (computed) | Computed | — | computed | Cash 448,011 + equity 1,020,000 + all other 0 = 1,468,011, summed across the director compensation table rows.machine: formula: Σ = 1,468,011 |
| 16 | AxoGen, Section 10b CEO total | DEF 14A | 2026-04-29 | 0000805928-26-000057 | CEO total compensation as printed in AxoGen's own proxy. As printed: 9,047,454. Filing ↗machine: r2 · c45 · span 557309–557318 |
| 17 | Si-BONE, Section 10b CEO total | DEF 14A | 2026-04-21 | 0001459839-26-000049 | CEO total compensation as printed in Si-BONE's own proxy. As printed: 7,453,235. Filing ↗machine: r3 · c18 · span 626969–626978 |
| 18 | Pulse Biosciences, Section 10b CEO total | DEF 14A | 2026-05-11 | 0001437749-26-016006 | CEO total compensation as printed in Pulse Biosciences's own proxy. As printed: 7,427,899. Filing ↗machine: r1 · c21 · span 428112–428121 |
| 19 | CareDx, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001217234-26-000028 | CEO total compensation as printed in CareDx's own proxy. As printed: 7,179,699. Filing ↗machine: t113 · r3 · c9 · span 1893652–1893661 |
| 20 | Treace Medical Concepts, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001630627-26-000005 | CEO total compensation as printed in Treace Medical Concepts's own proxy. As printed: 5,405,190. Filing ↗machine: t81 · r4 · c16 · span 1034150–1034159 |
| 21 | RxSight, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187240 | CEO total compensation as printed in RxSight's own proxy. As printed: 4,650,661. Filing ↗machine: t20 · r4 · c24 · span 978530–978539 |
| 22 | CVRx, Section 10b CEO total | DEF 14A | 2026-04-20 | 0001140361-26-015657 | CEO total compensation as printed in CVRx's own proxy. As printed: 3,905,801. Filing ↗ |
| 23 | Senseonics Holdings, Section 10b CEO total | DEF 14A | 2026-04-09 | 0001104659-26-041541 | CEO total compensation as printed in Senseonics Holdings's own proxy. As printed: 3,347,959. Filing ↗machine: r1 · c47 · span 527980–527989 |
| 24 | OrthoPediatrics, Section 10b CEO total | DEF 14A | 2026-04-20 | 0001425450-26-000027 | CEO total compensation as printed in OrthoPediatrics's own proxy. As printed: 3,331,481. Filing ↗machine: r2 · c36 · span 363407–363416 |
| 25 | Sight Sciences (subject), Section 10b CEO total | DEF 14A | 2026-04-22 | 0001140361-26-016138 | CEO total compensation as printed in Sight Sciences's own proxy. As printed: 2,005,608. Filing ↗machine: r2 · c18 · span 798195–798204 |
| 26 | Zynex, Section 10b CEO total | DEF 14A | 2025-03-28 | 0001558370-25-004019 | CEO total compensation as printed in Zynex's own proxy. As printed: 991,810. Filing ↗machine: t66 · r5 · c14 · span 277902–277909 |
| 27 | iRadimed Corporation, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001628280-26-028903 | CEO total compensation as printed in iRadimed Corporation's own proxy. As printed: 780,598. Filing ↗machine: r3 · c36 · span 177624–177631 |
| 28 | Section 10a, Si-BONE reciprocity | DEF 14A | — | 0001459839-26-000049 | Si-BONE names Sight Sciences in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 29 | Section 10a, Zynex reciprocity | DEF 14A | — | 0001558370-25-004019 | Zynex's most recent proxy was read; its disclosed peer group does not include Sight Sciences. Filing ↗ |
| 30 | Section 10a, CareDx reciprocity | DEF 14A | — | 0001217234-26-000028 | CareDx's most recent proxy was read; its disclosed peer group does not include Sight Sciences. Filing ↗ |
| 31 | Section 10a, AxoGen reciprocity | DEF 14A | — | 0000805928-26-000057 | AxoGen's most recent proxy was read; its disclosed peer group does not include Sight Sciences. Filing ↗ |
| 32 | Section 10a, Pulse Biosciences reciprocity | DEF 14A | — | 0001437749-26-016006 | Pulse Biosciences's most recent proxy was read; its disclosed peer group does not include Sight Sciences. Filing ↗ |
| 33 | Section 10a, RxSight reciprocity | DEF 14A | — | 0001193125-26-187240 | RxSight's most recent proxy was read; its disclosed peer group does not include Sight Sciences. Filing ↗ |
| 34 | Section 10a, Treace Medical Concepts reciprocity | DEF 14A | — | 0001630627-26-000005 | Treace Medical Concepts's most recent proxy was read; its disclosed peer group does not include Sight Sciences. Filing ↗ |